1
Andrew J Murphy, George D Yancopoulos: Methods of modifying eukaryotic cells. Regeneron Pharmaceuticals, Gail M Kempler, Linda O Palladino, July 22, 2003: US06596541 (120 worldwide citation)

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of clon ...


2
William Poueymirou, Thomas M Dechiara, Wojtek Auerbach, David Frendewey, David M Valenzuela: Method for generating an animal homozygous for a genetic modification. Regeneron Pharmaceuticals, Valeta Gregg Esq, Ying Zi Yang, Tor E Smeland Esq, November 13, 2007: US07294754 (67 worldwide citation)

Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant or complete contribution to all tissues from the donor cells and is capable of transmitting the d ...


3
Aris N Economides, Andrew J Murphy, David M Valenzuela, George D Yancopoulos: Methods of modifying eukaryotic cells. Regeneron Pharmaceuticals, Linda O Palladino, Gail M Kempler, July 1, 2003: US06586251 (64 worldwide citation)

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of clon ...


4
Mark W Sleeman, Joel H Martin, Tammy T Huang, Douglas MacDonald: High affinity human antibodies to PCSK9. Regeneron Pharmaceuticals, Valeta Gregg, Frank R Cottingham, November 22, 2011: US08062640 (57 worldwide citation)

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with l ...


5

6
Andrew J Murphy, George D Yancopoulos: Methods of modifying eukaryotic cells. Regeneron Pharmaceuticals, Valeta Gregg Esq, September 12, 2006: US07105348 (53 worldwide citation)

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of clon ...


7
Papadopoulos Nicholas J, Martin Joel H, Smith Eric, Noguera Troise Irene, Thurston Gavin: Human antibodies to human delta like ligand 4. Regeneron Pharmaceuticals, Papadopoulos Nicholas J, Martin Joel H, Smith Eric, Noguera Troise Irene, Thurston Gavin, sGREGG Valeta, June 26, 2008: WO/2008/076379 (53 worldwide citation)

An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDII4) and blocks hDII4 binding to a Notch receptor. The human anti- hDII4 antibody or antibody fragment binds hDII4 with an affinity of ≤ 500 pM, as measured by surface plasmon resona ...


8
Andrew J Murphy, George D Yancopoulos: Methods of modifying eukaryotic cells. Regeneron Pharmaceuticals, Foley Hoag, August 6, 2013: US08502018 (52 worldwide citation)

A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of clon ...


9
Eric J Nestler, Melissa T Berhow, Dana Beitner Johnson, David S Russell, Ronald M Lindsay: Methods for treating addictive disorders. Regeneron Pharmaceuticals, Yale University, Klauber & Jackson, September 17, 1996: US05556837 (50 worldwide citation)

The present invention is broadly directed to treatment of an addictive disease or disorder. In particular, the invention relates to inhibiting or reversing the biochemical and neurophysiological changes that correlate with behavioral changes of addictive diseases or disorders. The method of the inve ...


10
Neil Stahl, George D Yancopoulos: Receptor based antagonists and methods of making and using. Regeneron Pharmaceuticals, Robert J Cobert, Gail M Kempler, Linda O Palladino, October 29, 2002: US06472179 (50 worldwide citation)

The present invention provides a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide.